Patents Represented by Attorney Nicole S. Woods

Find this attorney in the Justia Lawyer Directory

  • Antibodies against CSF-1R
    Patent number: 8263079
    Abstract: The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 11, 2012
    Assignee: ImClone, LLC
    Inventors: Jacqueline Francoise Doody, Yanxia Li
  • Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof
    Patent number: 8133489
    Abstract: The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 13, 2012
    Assignee: ImClone LLc
    Inventors: Daniel Pereira, Jennifer O'Toole
  • Antibodies against PDGFRa
    Patent number: 8128929
    Abstract: The invention provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFR? and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: March 6, 2012
    Assignee: ImClone LLC
    Inventors: Nick Loizos, Jim Huber
  • Anti-FLT3 antibodies
    Patent number: 8071099
    Abstract: The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: December 6, 2011
    Assignee: ImClone, LLC
    Inventors: Yiwen Li, Dan Lu, David Surguladze, James Robert Tonra
  • IGF-IR antagonists as adjuvants for treatment of prostate cancer
    Patent number: 7972600
    Abstract: The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: July 5, 2011
    Assignees: ImClone LLC, University of Washington
    Inventors: Dale L. Ludwig, Stephen R. Plymate
  • Fully human antibodies directed against the human insulin-like growth factor-1 receptor
    Patent number: 7968093
    Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: June 28, 2011
    Assignee: ImClone LLC
    Inventor: Dale L Ludwig
  • Antibodies that bind specifically to human RON protein
    Patent number: 7947811
    Abstract: The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: May 24, 2011
    Assignee: ImClone LLC
    Inventors: Daniel Pereira, Jennifer O'Toole
  • PDGFR?-specific antibodies
    Patent number: 7740850
    Abstract: The invention is directed to novel PDGFR?-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR?-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: June 22, 2010
    Assignee: ImClone, LLC
    Inventors: Zhenping Zhu, Juqun Shen